{"schema":"https://pith.science/schemas/pith-integrity/v1.json","pith_number":"2607.23733","arxiv_id":"2607.23733","integrity":{"available":true,"endpoint":"/pith/2607.23733/integrity.json","summary":{"critical":0,"advisory":1,"informational":0,"by_detector":{"doi_compliance":{"total":1,"critical":0,"advisory":1,"informational":0}}},"clean":false,"detectors_run":[{"name":"doi_title_agreement","version":"1.0.0","status":"completed","ran_at":"2026-08-04T16:40:15.675055Z","findings_count":0},{"name":"doi_compliance","version":"1.1.0","status":"completed","ran_at":"2026-08-04T16:02:29.673268Z","findings_count":1},{"name":"ai_meta_artifact","version":"1.0.0","status":"skipped","ran_at":"2026-08-04T08:08:48.261335Z","findings_count":0},{"name":"claim_evidence","version":"1.0.0","status":"completed","ran_at":"2026-08-02T13:08:26.214754Z","findings_count":0},{"name":"cited_work_retraction","version":"1.0.0","status":"completed","ran_at":"2026-07-28T17:54:22.554036Z","findings_count":0}],"findings":[{"detector":"doi_compliance","finding_type":"recoverable_identifier","severity":"advisory","verdict_class":"incontrovertible","note":"DOI is split by whitespace or line breaks in the printed bibliography. Reconstructed DOI 10.1067/mcp.2001.115446 resolves to 'Risks in new drug development: Approval success rates for investigational drugs'. A reader following the printed text alone cannot reach it.","detected_doi":"10.1067/mcp.2001.115446","detected_arxiv_id":null,"ref_index":16,"audited_at":"2026-07-30T14:41:41.548910Z"}],"snapshot_sha256":"8ea1fa2969e71b866d7ecf3b0d1c90ed457f401a2ef56a5f4c41e78a9e434fcf"},"events":[{"event_id":13951,"event_type":"pith.integrity.v1","payload_sha256":"c4486924736e3fe7c353fadf9fb2a3ed96877647f3bfcbfcb28101620f0feaf0","signature_b64":null,"signing_key_id":null,"created_at":"2026-07-30T14:46:18.684879+00:00","payload":{"note":"DOI is split by whitespace or line breaks in the printed bibliography. Reconstructed DOI 10.1067/mcp.2001.115446 resolves to 'Risks in new drug development: Approval success rates for investigational drugs'. A reader following the printed text alone cannot reach it.","snippet":"Joseph A. DiMasi. Risks in new drug development: Approval success rates for investigational drugs.Clinical Pharmacology & Therapeutics, 69(5):297–307, 2001. doi: 10.1067/mcp.2001. 115446","arxiv_id":"2607.23733","detector":"doi_compliance","evidence":{"ref_index":16,"verdict_class":"incontrovertible","resolved_title":"Risks in new drug development: Approval success rates for investigational drugs","printed_excerpt":"10.1067/mcp.2001","reconstructed_doi":"10.1067/mcp.2001.115446"},"severity":"advisory","ref_index":16,"audited_at":"2026-07-30T14:41:41.548910Z","event_type":"pith.integrity.v1","detected_doi":"10.1067/mcp.2001.115446","detector_url":"https://pith.science/pith-integrity-protocol#doi_compliance","external_url":null,"finding_type":"recoverable_identifier","evidence_hash":"06892b5becfecf188bb7b3766042298fa4a4f11b0829a709d0129cf372ff6359","paper_version":1,"verdict_class":"incontrovertible","resolved_title":"Risks in new drug development: Approval success rates for investigational drugs","detector_version":"1.1.0","detected_arxiv_id":null}}],"endpoint_self":"/pith/2607.23733/integrity.json","protocol_url":"https://pith.science/pith-integrity-protocol"}